Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 332

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part II, Item 6
Chunk 332
---
Item 6. Exhibits

EXHIBIT INDEX

Incorporated by ReferenceFiled/FurnishedHerewithExhibit NumberExhibit DescriptionFormFile No.ExhibitFilingDate3.1Amended and Restated Certificate of Incorporation of Immuneering Corporation10-Q001-406753.19/9/20213.2Amended and Restated Bylaws of Immuneering Corporation8-K001-406753.12/2/20244.1Form of Pre-Funded Warrant8-K001-406754.18/25/20254.2Form of Purchase Warrant8-K001-406754.28/25/202510.1#Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective August 12, 2025*10.2Equity Distribution Agreement, dated as of August 13, 2025, by and between Immuneering Corporation and Piper Sandler & Co.S-3333-2895891.28/13/202510.3##Form of Securities Purchase Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the investors party thereto8-K001-4067510.18/25/202510.4Form of Registration Rights Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the investors party thereto8-K001-4067510.28/25/202510.5##Securities Purchase Agreement, dated as of September 24, 2025, by and between Immuneering Corporation and Aventis Inc.8-K001-4067510.19/24/202531.1Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).*31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).*32.1Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350.**32.2Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350.**

100

Table of Contents

Incorporated by ReferenceFiled/FurnishedHerewithExhibit NumberExhibit DescriptionFormFile No.ExhibitFilingDate101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.*101.SCH